According to the research report titled ‘Prurigo Nodularis Treatment Market Size By Product (Antihistamines, Capsaicin Cream, Corticosteroids, Emollients), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021 – 2027’, available with MarketStudyReport, global prurigo nodularis treatment market is likely to generate substantial returns by the end of the forecast period.
 

Growing demand for advanced healthcare products as well as better medications, escalating investments in R&D activities, and rising adoption of antihistamines are the primary growth stimulants for global prurigo nodularis treatment market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3793265/

Based on product landscape, the report claims that antihistamines segment is predicted to expand at 5.1% CAGR during 2021-2027, primarily due to its widespread adoption in first-line therapy for allergic reactions. Antihistamines are available in liquids, pills, chewable tablets, capsules as well as in injectable forms.

In terms of distribution channel, the hospital pharmacies segment captured 27.5% share in global prurigo nodularis treatment market in 2020 and is expected to register continuous growth throughout the study period. Surging demand for better medications and high patient volume in hospitals are fueling the segmental size.

Considering the geographical landscape, U.S. accounted for USD 200 million in North America prurigo nodularis treatment market and is anticipated to showcase a robust CAGR through 2027. Rising R&D investments, focus towards using advanced products, and rapid launch of innovative therapies by local players are complementing the business dynamics in the United States.

The prominent companies operating in global prurigo nodularis treatment market are Galderma S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Sanofi S.A., Merck & Co. Inc., Pfizer Inc., and Johnson & Johnson among others.